Ejlertsen Bent, Jensen Maj-Britt, Rank Fritz, Rasmussen Birgitte B, Christiansen Peer, Kroman Niels, Kvistgaard Marianne E, Overgaard Marie, Toftdahl Dorte B, Mouridsen Henning T
Department of Oncology, Bldg 4262 Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
J Natl Cancer Inst. 2009 May 20;101(10):729-35. doi: 10.1093/jnci/djp090. Epub 2009 May 12.
Lymphovascular invasion has been associated with poor prognosis in women with breast cancer, but it is unclear whether the presence of lymphovascular invasion should be considered sufficient to reclassify breast cancer patients who are at a low risk of recurrence into a high-risk category.
Of the 16,172 patients with operable breast cancer who were entered into the Danish Breast Cancer Cooperative Group Registry from January 1, 1996, to December 31, 2002, lymphovascular invasion was classified at primary diagnosis in 16,121 patients as present (n = 2453, 15%) or as absent (n = 13,206, 82%). Patients with at least one of the risk criteria (positive lymph nodes, tumor size > 2 cm, high grade, hormone receptor-negative tumor, or younger than 35 years) were assigned to the high-risk group; the other patients were assigned to the low-risk group. All procedures, including report forms, central review, and querying, were specified in advance. Kaplan-Meier analyses were used to estimate disease-free intervals and overall survival rates among patients with and without lymphovascular invasion, and multivariable analysis was used to adjust for differences in baseline characteristics and therapy. All statistical tests were two-sided.
Complete follow-up was achieved for 15,659 patients. The median estimated potential follow-up was 6.4 years for invasive disease-free interval and 7.7 years for overall survival. Invasive disease-free interval and overall survival were statistically significantly associated with lymphovascular invasion within the high-risk group (hazard ratio [HR] for invasive disease = 2.29, 95% confidence interval [CI] = 2.14 to 2.45, P < .001; and HR for death = 2.42, 95% CI = 2.25 to 2.61, P < .001) but not within the low-risk group. At 5 years after surgery, 65.4% (95% CI = 63.5% to 67.3%) and 85.2% (95% CI = 84.5% to 85.9%) of those in the high-risk group with and without lymphovascular invasion were alive; 98.1% (95% CI = 87.6% to 99.7%) and 94.1% (95% CI = 93.2% to 94.8%) of those in the low-risk group with and without lymphovascular invasion were alive. These differences persisted in a multivariable analysis, and for overall survival, a statistically significant interaction (P = .03) was observed between lymphovascular invasion and risk group.
In this prospective population-based study, lymphovascular invasion was not an independent high-risk criterion. Lymphovascular invasion should not by itself be considered sufficient to move patients from a low-risk group to a high-risk group.
淋巴管浸润与乳腺癌女性患者的预后不良相关,但尚不清楚淋巴管浸润的存在是否足以将复发风险低的乳腺癌患者重新分类为高风险类别。
在1996年1月1日至2002年12月31日进入丹麦乳腺癌协作组登记处的16172例可手术乳腺癌患者中,16121例患者在初次诊断时淋巴管浸润被分类为存在(n = 2453,15%)或不存在(n = 13206,82%)。具有至少一项风险标准(阳性淋巴结、肿瘤大小>2 cm、高级别、激素受体阴性肿瘤或年龄小于35岁)的患者被分配到高风险组;其他患者被分配到低风险组。所有程序,包括报告表、中心审查和查询,均预先规定。采用Kaplan-Meier分析估计有和无淋巴管浸润患者的无病间期和总生存率,并采用多变量分析调整基线特征和治疗的差异。所有统计检验均为双侧。
15659例患者实现了完全随访。侵袭性无病间期的中位估计潜在随访时间为6.4年,总生存为7.7年。在高风险组中,侵袭性无病间期和总生存与淋巴管浸润在统计学上显著相关(侵袭性疾病的风险比[HR]=2.29,95%置信区间[CI]=2.14至2.45,P<.001;死亡的HR = 2.42,95%CI = 2.25至2.61,P<.001),但在低风险组中并非如此。术后5年,高风险组中有和无淋巴管浸润的患者分别有65.4%(95%CI = 63.5%至67.3%)和85.2%(95%CI = 84.5%至85.9%)存活;低风险组中有和无淋巴管浸润的患者分别有98.1%(95%CI = 87.6%至99.7%)和94.1%(95%CI = 93.2%至94.8%)存活。这些差异在多变量分析中持续存在,并且对于总生存,在淋巴管浸润和风险组之间观察到统计学上显著的相互作用(P = .03)。
在这项基于人群的前瞻性研究中,淋巴管浸润不是一个独立的高风险标准。淋巴管浸润本身不应被视为足以将患者从低风险组转移到高风险组。